Antidiabetic Therapy and Rate of Severe Hypoglycaemia in Patients
                    with Type 2 Diabetes and Chronic Kidney Disease of Different Stages – A
                    Follow-up Analysis of Health Insurance Data from Germany

Martin Busch; Thomas Lehmann; Gunter Wolf; Christian Günster; Ulrich Alfons Müller; Nicolle Müller

doi:10.1055/a-1129-6699

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2021; 129(11): 821-830
DOI: 10.1055/a-1129-6699

Article

Antidiabetic Therapy and Rate of Severe Hypoglycaemia in Patients with Type 2 Diabetes and Chronic Kidney Disease of Different Stages – A Follow-up Analysis of Health Insurance Data from Germany

Authors

Martin Busch

¹Department of Internal Medicine III, University Hospital Jena, Jena, Germany
Thomas Lehmann

²Center for Clinical Studies, University Hospital Jena, Jena, Germany
Gunter Wolf

¹Department of Internal Medicine III, University Hospital Jena, Jena, Germany
Christian Günster

³Research Institute of the Local Health Care Funds, Berlin, Germany
Ulrich Alfons Müller

¹Department of Internal Medicine III, University Hospital Jena, Jena, Germany
Nicolle Müller

¹Department of Internal Medicine III, University Hospital Jena, Jena, Germany

Abstract

Background The presence of chronic kidney disease (CKD) influences the type of antiglycaemic therapy and the risk for hypoglycaemia.

Methods In 2006, 2011 and 2016 health insurance data of people with diabetes type 2 were screened for CKD and the presence of severe hypoglycaemia (sHypo). The type of antihyperglycaemic therapy was recorded due to Anatomical Therapeutic Chemical (ATC) codes up to 3 months before suffering sHypo.

Results The prevalence of CKD increased from 5.3% in 2006 to 7.3% in 2011 and 11.2% in 2016. Insulin-based therapies were used in 39.0, 39.1, and 37.9% of patients with, but only in 17.7, 17.4, and 18.8% of patients without CKD. Although the proportion of the CKD stages 1, 2 and 5 decreased, CKD stages 3 and 4 increased. The proportion of sHypo in CKD declined from 2006 (3.5%) to 2011 (3.0%) and 2016 (2.2%) but was still more than 10 times higher as compared to type 2 diabetic patients without CKD (0.3/0.2/0.2%) conferring a significantly higher probability of sHypo (OR 9.30, 95%CI 9.07–9.54) in CKD. The probability of sHypo was significantly lower in 2016 than in 2006 both in patients with (OR 0.58; CI 0.55–0.61) and without CKD (OR 0.70; CI 0.68–0.73).

Conclusion The prevalence of CKD increased from 2006 to 2016. Patients with CKD exhibited a 9-fold increased probability of sHypo, especially in patients treated with insulin plus oral anti-diabetic drugs. However, the rate and risk for sHypo decreased over time, probably as a consequence of new antidiabetic treatment options, better awareness of sHypo, and changed therapy goals.

Key words

complications - glycaemic control - hemoglobin A1C - insulin therapy - oral antidiabetic drugs

Full Text

References

References
1 Stratton IM, Adler AI, Neil HA. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 321: 405-412
2 Group UKPDS Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853
3 Group TDCaCTR The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986
4 Ray KK, Seshasai SR, Wijesuriya S. et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772
5 Tuttle KR, Bakris GL, Bilous RW. et al. Diabetic kidney disease: A report from an ADA Consensus Conference. Am J Kidney Dis 2014; 64: 510-533
6 Muller N, Lehmann T, Gerste B. et al. Increase in the incidence of severe hypoglycaemia in people with Type 2 diabetes in spite of new drugs: Analysis based on health insurance data from Germany. Diabet Med 2017; 34: 1212-1218
7 Inzucchi SE, Bergenstal RM, Buse JB. et al. Management of hyperglycaemia in type 2 diabetes, 2015: A patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015; 58: 429-442
8 Solini A, Penno G, Bonora E. et al. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: Findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study. J Am Geriatr Soc 2013; 61: 1253-1261
9 del Pozo-Fernandez C, Pardo-Ruiz C, Sanchez-Botella C. et al. Discrepancies among consensus documents, guidelines, clinical practice and the legal framework for the treatment of type 2 diabetes mellitus patients. Nefrologia 2012; 32: 367-373
10 Titze S, Schmid M, Kottgen A. et al. Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort. Nephrol Dial Transplant 2015; 30: 441-451
11 Eckardt KU, Barthlein B, Baid-Agrawal S. et al. The German Chronic Kidney Disease (GCKD) study: Design and methods. Nephrol Dial Transplant 2012; 27: 1454-1460
12 Busch M, Nadal J, Schmid M. et al. Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease - cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort. BMC Nephrol 2016; 17: 59
13 Shurraw S, Hemmelgarn B, Lin M. et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: A population-based cohort study. Arch Intern Med 2011; 171: 1920-1927
14 Muller N, Heller T, Freitag MH. et al. Healthcare utilization of people with type 2 diabetes in Germany: An analysis based on health insurance data. Diabet Med 2015; 32: 951-957
15 Rafaniello C, Arcoraci V, Ferrajolo C. et al. Trends in the prescription of antidiabetic medications from 2009 to 2012 in a general practice of Southern Italy: A population-based study. Diabetes Res Clin Pract 2015; 108: 157-163
16 Yurgin N, Secnik K, Lage MJ. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: A retrospective database study. Clin Ther 2007; 29: 316-325
17 Stone MA, Charpentier G, Doggen K. et al. Quality of care of people with type 2 diabetes in eight European countries: Findings from the Guideline Adherence to Enhance Care (GUIDANCE) study. Diabetes Care 2013; 36: 2628-2638
18 Jager KJ, Fraser SDS. The ascending rank of chronic kidney disease in the global burden of disease study. Nephrol Dial Transplant 2017; 32: ii121-ii128
19 Coresh J, Selvin E, Stevens LA. et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047
20 Goldenberg RM, Berall M, Chan CTM. et al. Managing the course of kidney disease in adults with type 2 diabetes: From the old to the new. Can J Diabetes 2018; 42: 325-334
21 Johansen OE, Birkeland KI. Defining the role of repaglinide in the management of type 2 diabetes mellitus: A review. Am J Cardiovasc Drugs 2007; 7: 319-335
22 Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials. Lancet 2007; 370: 1129-1136
23 Fioretto P, Muollo B, Faronato PP. et al. Relationships among natriuresis, atrial natriuretic peptide and insulin in insulin-dependent diabetes. Kidney Int 1992; 41: 813-821
24 Gilbert RE, Krum H. Heart failure in diabetes: Effects of anti-hyperglycaemic drug therapy. Lancet 2015; 385: 2107-2117
25 Lovshin JA, Barnie A, DeAlmeida A. et al. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care 2015; 38: 132-139
26 Marso SP, Bain SC, Consoli A. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834-1844
27 Marso SP, Daniels GH, Brown-Frandsen K. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322
28 Mann JFE, Orsted DD, Brown-Frandsen K. et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377: 839-848
29 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128
30 Wanner C, Inzucchi SE, Lachin JM. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323-334
31 Neal B, Perkovic V, Mahaffey KW. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-657
32 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wis-senschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes – Langfassung, 1. Auflage. Version 4. 2013, zuletzt geändert: November 2014. Available from: www.dm-therapie.versorgungsleitlinien.de;[cited: 11.09.2019],
33 Zoungas S, Patel A, Chalmers J. et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363: 1410-1418
34 Moen MF, Zhan M, Hsu VD. et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1121-1127
35 Miller ME, Bonds DE, Gerstein HC. et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010; 340: b5444
36 Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 2004; 17: 365-370
37 Alsahli M, Gerich JE. Renal glucose metabolism in normal physiological conditions and in diabetes. Diabetes Res Clin Pract 2017; 133: 1-9
38 Balkau B, Metzger M, Andreelli F. et al. Impact of sex and glucose-lowering treatments on hypoglycaemic symptoms in people with type 2 diabetes and chronic kidney disease. The French Chronic Kidney Disease - Renal Epidemiology and Information Network (CKD-REIN) Study. Diabetes Metab. 2019 45. 175-183
39 Weir MA, Gomes T, Mamdani M. et al. Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide: A population-based nested case-control study. Nephrol Dial Transplant 2011; 26: 1888-1894
40 Kloos C, Muller N, Hartmann P. et al. High quality of diabetes care based upon individualised treatment goals - A cross sectional study in 4784 patients in Germany. Exp Clin Endocrinol Diabetes 2016; 124: 294-299
41 Lo C, Toyama T, Wang Y. et al. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database Syst Rev 2018; 9: CD011798
42 Anguiano Gomez L, Lei Y, Kumar Devarapu S. et al. The diabetes pandemic suggests unmet needs for ‘CKD with diabetes’ in addition to ‘diabetic nephropathy’-implications for pre-clinical research and drug testing. Nephrol Dial Transplant 2018; 33: 1292-1304
43 Davies MJ, D'Alessio DA, Fradkin J. et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61: 2461-2498
44 Cosentino F, Grant PJ, Aboyans V. et al. ESC Scientific Document Group 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2019; 31 pii ehz486.

Supplementary Material

Supplementary Material (PDF)